Bristol Myers Squibb will buy Mirati Therapeutics in a deal worth up to $5.8 billion, or $58 per share, the biopharmaceutical company announced Sunday.
Bristol Myers Squibb said Sunday it will acquire drugmaker Mirati Therapeutics in a deal worth up to $5.8 billion, adding to its oncology business portfolio. The company said it will pay $58 per share in cash. As part of the deal, Mirati stockholders will also receive one non-tradeable contingency value for each Mirati share held, potentially worth $12 per share in cash while representing an additional $1 billion of value opportunity, according to the announcement.
With multiple targeted oncology assets including Krazati, Mirati is another important step forward in our efforts to grow our diversified oncology portfolio and further strengthen Bristol Myers Squibb’s pipeline for the latter half of the decade and beyond," Bristol Myers Squibb CFO and CEO-elect Chris Boerner said in a statement.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 BillionDeal expands pharmaceutical company’s portfolio of cancer drugs
Lire la suite »
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billionMirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others, to its...
Lire la suite »
Bristol-Myers Squibb to acquire Mirati in $5.8 billion dealBristol-Myers Squibb (BMY.N) on Sunday said it will acquire Mirati Therapeutics (MRTX.O) in a transaction that values the cancer drugmaker at up to $5.8 billion.
Lire la suite »
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion dealBristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
Lire la suite »
Bristol-Myers Squibb shells out $5.8B for Mirati: 5 big deal reportsBristol-Myers Squibb shells out $5.8B for Mirati: 5 big deal reports
Lire la suite »
Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 BillionThe acquisition will help boost revenue by offsetting upcoming competition from generics for Bristol Myers Squibb’s best-selling products.
Lire la suite »